Rheumatoid Arthritis

JAK=Janus kinase; JAKi=Janus kinase inhibitor; MOA=mechanism of action; RA=rheumatoid arthritis.
References: 1. XELJANZ/XELJANZ XR [prescribing information]. New York, NY: Pfizer Inc.; December 2019. 2. Data on file. Pfizer Inc., New York, NY. 3. Fleischmann R, Kremer J, Cush J, et al; for the ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507. 4. Lee EB, Fleischmann R, Hall S, et al; for the ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386.